Evidence map›Paper›PMID 39548233›Full record

ReviewNature reviews. Cardiology2025

Trials and tribulations of cell therapy for heart failure: an update on ongoing trials.

Jianyi Jay Zhang, Steven M Pogwizd, Keiichi Fukuda, Wolfram-Hubertus Zimmermann, Chengming Fan, Joshua M Hare, Roberto Bolli, Philippe Menasché

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Past, Present and Future of Regenerative Gene Therapy for Ischemic Heart Failure.Journal of cardiovascular translational research · 2026
    Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Heart-derived endogenous stem cells.Molecular biology reports · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jianyi Jay ZhangDepartment of Biomedical Engineering, School of Medicine, School of Engineering, The University of Alabama at Birmingham, Birmingham, AL, USA. jayzhang@uab.edu.
Steven M PogwizdDivision of Cardiovascular Disease, Department of Medicine, School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA.
Keiichi FukudaDepartment of Cardiology, Keio University, Tokyo, Japan.
Wolfram-Hubertus ZimmermannInstitute of Pharmacology and Toxicology, University Medical Center Göttingen - Georg-August-University, Göttingen, Germany.ORCID 0000-0003-1190-4040
Chengming FanDepartment of Cardiovascular Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.ORCID 0000-0003-0497-1798
Joshua M HareDepartment of Medicine, Interdisciplinary Stem Cell Institute (ISCI), University of Miami, Miami, FL, USA.
Roberto BolliInstitute of Molecular Cardiology, University of Louisville, Louisville, KY, USA.
Philippe MenaschéDepartment of Cardiovascular Surgery, Hôpital Européen Georges Pompidou, Université de Paris, PARCC, INSERM, Paris, France.

Funding

Integrated Cellular and Tissue Engineering for Ischemic Heart DiseaseU01HL134764 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BURSAC, NENAD, KAMP, TIMOTHY J. · 2016 to 2022
$7.7M
NHLBI NIH HHS U01 HL134764
6 · The paper itself

Abstract

Heart failure (HF) remains a leading cause of mortality, responsible for 13% of all deaths worldwide. The prognosis for patients with HF is poor, with only a 50% survival rate within 5 years. A major challenge of ischaemia-driven HF is the loss of cardiomyocytes, compounded by the minimal regenerative capacity of the adult heart. To date, replacement of irreversibly damaged heart muscle can only be achieved by complete heart transplantation. In the past 20 years, cell therapy has emerged and evolved as a promising avenue for cardiac repair and regeneration. During this time, cell therapy for HF has encountered substantial barriers in both preclinical studies and clinical trials but the field continues to progress and evolve from lessons learned from such research. In this Review, we provide an overview of ongoing trials of cell-based and cell product-based therapies for the treatment of HF. Findings from these trials will facilitate the clinical translation of cardiac regenerative and reparative therapies not only by evaluating the safety and efficacy of specific cell-based therapeutics but also by establishing the feasibility of novel or underexplored treatment protocols such as repeated intravenous dosing, personalized patient selection based on pharmacogenomics, systemic versus intramural cell delivery, and epicardial engraftment of engineered tissue products.

Indexed as

Cell- and Tissue-Based TherapyHeart FailureMyocytes, CardiacStem Cell TransplantationAnimalsClinical Trials as TopicHumansRegenerationTreatment Outcome

Identifiers

PMID39548233

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.